CD4 and neoplasm: Tregs can thus inhibit the anti-tumor immune response by suppressing the activity of both tumor-specific (CD8+ cytotoxic T lymphocytes and CD4+ T helper cells) and tumor unspecific effector cells (natural killer [NK] and NK T cells) [8].